TROP2 Lung Cancer Tissue Study
Part of Cancer, Lungs & breathing clinical trials.
This research study analyzes lung cancer tissue samples to understand a protein called TROP2 and how it might help guide treatment decisions. You may qualify if you have non-squamous lung cancer and haven't received prior systemic chemotherapy or immunotherapy for advanced disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older at the time of tissue sampling
- Diagnosed with non-squamous non-small cell lung cancer (NSCLC), either advanced (Stage IIIB–IV without prior treatment) or early-stage with available surgical tissue
- Your tumor does not have certain genetic mutations (EGFR, ALK, ROS1) or other alterations (NTRK, BRAF, RET, MET, HER2, KRAS) that have targeted therapies available
- Your tumor's PD-L1 status (an immune marker) has already been tested and documented
- Able to provide adequate tissue samples—at least 5 slides from a biopsy or surgical specimen less than 2 years old
- No active tuberculosis or severe lung problems (such as recent blood clots, severe asthma, or severe COPD) at the time of tissue collection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects and analyzes lung cancer tissue samples to understand genetic differences that may help guide future treatment. You'll provide a tissue sample (either from a biopsy or prior surgery), and researchers will study it—no treatment is given in this study.
This trial uses a special PET scan to find a protein called Trop-2 on your cancer cells. It helps doctors decide if a targeted treatment (Trop-2 ADC) might work for you.
This trial tests a new drug called GQ1010 for people with advanced solid tumors that have stopped responding to standard treatments. The drug targets a protein called Trop-2 on cancer cells to try to shrink tumors or slow their growth.
This trial uses advanced gene sequencing technology on blood and tumor tissue samples from people with non-small cell lung cancer. The goal is to see if this testing can help doctors better predict which treatments will work and detect if the cancer comes back early.
This trial tests whether two different PET scans can help doctors see how well a new type of targeted therapy (called a TROP2 ADC) is working in people with a specific kind of advanced lung cancer that has stopped responding to standard pills. The goal is to find the best way to monitor treatment and potentially improve outcomes.
This trial tests an investigational cell therapy called Trop2 CAR-NK for people with advanced non-small cell lung cancer that has come back after standard treatments. The therapy uses your own immune cells (natural killer cells) that are specially trained to find and attack cancer cells that carry the Trop2 protein. This may help shrink tumors or slow the cancer's growth.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.